...
首页> 外文期刊>Modern rheumatology >Cryopyrin-associated periodic syndromes: background and therapeutics.
【24h】

Cryopyrin-associated periodic syndromes: background and therapeutics.

机译:隐索蛋白相关的周期性综合征:背景和治疗方法。

获取原文
获取原文并翻译 | 示例
           

摘要

Cryopyrin-associated periodic syndromes (CAPS) are caused by mutations of the gene encoding the NLR family protein NLRP3, which together with caspase-1 and adaptor proteins constitutes a protein complex termed the inflammasome. In innate immune reactions, a variety of stimuli activate the NLRP3 inflammasome, triggering caspase-1 to process proIL-1 and thus to produce mature IL-1. Excessive production of IL-1 by monocytes/macrophages is the central pathophysiology of CAPS, and daily injection of the IL-1 receptor antagonist anakinra rapidly ameliorates the inflammatory symptoms in most cases. Furthermore, double-blind, placebo-controlled clinical trials have recently confirmed the efficacy and safety of rilonacept, a fusion protein of the IL-1 receptor and IgG Fc, and canakinumab, a human anti-IL-1 monoclonal antibody, as novel long-lasting agents for treating CAPS.
机译:隐索蛋白相关的周期性综合征(CAPS)是由编码NLR家族蛋白NLRP3的基因突变引起的,该基因与caspase-1和衔接子蛋白一起构成了称为炎性体的蛋白复合物。在先天性免疫反应中,多种刺激激活NLRP3炎性体,触发caspase-1处理proIL-1,从而产生成熟的IL-1。单核细胞/巨噬细胞过量产生IL-1是CAPS的主要病理生理,在大多数情况下,每天注射IL-1受体拮抗剂anakinra可以迅速缓解炎症症状。此外,双盲,安慰剂对照的临床试验最近证实了IL-1受体与IgG Fc融合蛋白rilonacept和人抗IL-1单克隆抗体canakinumab的有效性和安全性。用于治疗CAPS的持久剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号